Our results suggest that efficient therapy or prevention of microangiopathy through inhibition of the erythrocyte-VWF interaction may decrease the rate of microangiopathic complications in various diseases, such as diabetes, HUS and sickle cell disease. Here, VWF is linked to diabetes mellitus.